(Including 8 months as ad-interim)Leading elafibranor (IQIRVO) launch in PBC globallyIndications:Rare liver disease- PBC (primary biliary cholangitis)- PSC (primary sclerosing cholangitis)

- Lead the strategic direction and the development and implementation of both the Medical Education and External Engagement plans with key experts, centers and medical societies,- Lead the insight-generation strategy and implementation,- Lead and executed the company presence in congresses (symposia, medical booth, HCPs engagement, and cross-functional alignment)- Lead the co-development of care networks for an ultra-rare musculoskeletal disorder,- Approved and provided direction for the market research and external-facing-material developed by different departments (marketing, communication, market access…),- Participated in the design of the global integrated brand and medical plan for the 4 assets,

Part of Actelion pharmaceuticals Ltd. Global Research & Development department, my role focused on different aspects of "ponesimod" development plan and pre-launch in multiple sclerosis (MS):- Managed 4 clinical studies (Phase II and III) from the scientific and medical side, and acted as the first scientific and medical contact with the study sites’ teams (France & BeNeLux)- Proposed innovative ideas to optimise the studies’ conduct from both the medical viewpoint and the patient experience,- Identified, initiated and fostered a collaborative relationship with Key Opinion Leaders (KOL) and external stakeholders (patient advocacy groups, institutions…),- Developed and coordinated regional & international advisory boards (KOL, patient advocacy groups…) to better understand their needs and the future drug’s positioning,- Created Actelion and Janssen medical and R&D booth, and the relevant medical material, for regional and international meetings (ECTRIMS, EAN, JNLF…),- Created educational material and provided training for external and internal stakeholders,- Participated, with Global and EMEA, in the elaboration of the drug’s (ponesimod) future launch strategy.

Participated in the leading and coordination of a Medical Affairs Excellence and Transformational Change Management program aiming to optimize the role of (no less than 600) MSLs & MSL Managers and their engagement with external stakeholders in the EMEA region.

- Acted as the SME (subject matter expert) for ponesimpd in MS (multiple sclerosis)- Informed, reviewed & approved external-facing company material (drug & therapeutic area related) ensuring scientific accuracy & relevance, and compliance with EU & local healthcare compliance rules

On behalf of Bayer Healthcare, and in contribution to Xarelto® (Rivaroxaban) success:- Presented medical and scientific information to various thought leaders, helping them better positioning Xarelto® in their therapeutic arsenal- Collaborated with sales representatives to optimise the medical communication impact

On behalf of a pharmaceutical company, in preparation for the EU launch of an innovative product (a drug/device combination):- Identified current market and therapeutic area needs, and conducted extended research (including 30+ interviews with EU KOLs) to prepare the launch strategy- Built strategy recommendations for medical and medico-economic communication, and negotiated product’s country specific price models for EU5 countries

Part of the immunology department:- Managed multiple research projects in immunology and oncology, from concept development to publication/presentation, within restraint budgets and timelines- Organised, with physicians and clinical investigators in EU and the Americas, patients’ identification and sample collection in accordance with ethical and legal frameworks- Presented scientific data in 10+ European and International scientific and medical congresses, and collected data, insuring competitive intelligence and scientific monitoring- Developed a broad network of contacts, and built collaboration projects with top research centres- Designed and developed a novel high throughput-analysis technique, and provided training for 35 EU platform managers

Master internship in Neuroscience : "Neuropeptide Y and its effect on 3 alpha,5 alpha-THP (tetrahydro progesterone) biogenesis in rat's Hippocampus and Amygdala"

Master internship in Molecular Biology and Virology: "Mechanistic study of HIV (Human Immunodeficiency Virus) RT (Reverse Transcriptase) inhibitors inducing DCT (Delayed Chain Termination)"

Summer internship in Microfluidics' applications in enzymes' function optimisation.